Maxim Comments On OncoSec Medical As It Takes IL-12 Immunopulse To Head And Neck Cancer

Maxim Group analyst Jason Kolbert is out today with his second note this week on OncoSec Medical (OTC:ONCS) maintaining a Buy rating with a $3.00 price target, following today’s conference call where the company discussed plans to expand its IL-12 Immunopulse platform to Head and Neck Cancer. 

Kolbert noted, “Why head and neck cancer? Like melanoma, this patient population has a high incidence of anti-PD-1 therapy non-responders. Oncosec’s intratumoral immunotherapy with IL-12 has been shown to increase ”Tumor-Infiltrating Lymphocytes’ (TILs) that kill tumor cells.”

The analyst concluded, “IL-12 Immunopulse upregulation of IL-12 in the tumor itself may be the key to ‘unmasking’ tumors to T cell attack, potentially further enhanced by increased susceptibility to checkpoint inhibitors like anti-PD-1 monoclonal antibodies. Oncosec’s approach may be applicable to many tumor types.”

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 4.5% and a 40.2% success rate. Kolbert has a -3.3% average return when recommending ONCS, and is ranked #759 out of 3401 analysts.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts